NCT04627285View on ClinicalTrials.gov

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

February 12, 2025

Study Completion Date

February 12, 2025

Conditions

Epilepsy

Interventions

DRUG

Lacosamide

"* Pharmaceutical form: Oral-solution~* Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period."

Trial Locations (15)

Unknown

Ep0151 620, Tbilisi

Ep0151 621, Tbilisi

Ep0151 622, Tbilisi

Ep0151 361, Budapest

Ep0151 362, Budapest

Ep0151 650, Chisinau

Ep0151 581, Bucharest

Ep0151 582, Iași

Ep0151 577, Timișoara

Ep0151 224, Taipei

Ep0151 602, Dnipro

Ep0151 609, Dnipropetrovsk

Ep0151 606, Kiev

Ep0151 682, Uzhhorod

Ep0151 603, Vinnytsia

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY

NCT04627285 - A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment | Biotech Hunter | Biotech Hunter